Clinical Trials on Hepatitis B Reactivation in Switzerland

Total 179 results

University Hospital, Basel, Switzerland

Terminated

Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine (SASL28)

Hepatitis, Chronic

Switzerland
GlaxoSmithKline

Completed

Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine

Hepatitis B

Belgium, Germany, Switzerland
University Hospital Inselspital, Berne

Completed

TAF for HIV-HBV With Renal Dysfunction

HIV and Hepatitis B Coinfection

Switzerland
Hoffmann-La Roche

Completed

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Chronic Hepatitis B

China, Korea, Republic of, Taiwan, Germany, United States, Singapore, Switzerland, Canada, Puerto Rico, Thailand, Israel, France, New Zealand, Poland, United Kingdom, Brazil, Australia
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
Pevion Biotech Ltd

Completed

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Chronic Hepatitis C

Switzerland
Bristol-Myers Squibb
Basel Institute of Clinical Epidemiology (BICE)

Completed

Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period

Hepatitis C

Switzerland
University Hospital, Basel, Switzerland

Completed

Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine

Hepatitis C

Switzerland
University of Zurich

Completed

Influence of Consecutive Strength- and Endurance Regimes on the Myonuclear Domain and Satellite Cell in the M. Vastus Lateralis of Old Healthy Men

Regeneration Potential of Healthy Old Men in Terms of Satellite Cell Activation

Switzerland
University Hospital, Geneva

Completed

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Chronic Hepatitis C

Switzerland
University of Zurich
PD Dr. rer. nat. Mathias Heikenwälder

Unknown

A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

Chronic HCV Hepatitis C

Switzerland
Ente Ospedaliero Cantonale, Bellinzona
Clinical Trial Unit Ente Ospedaliero Cantonale; Swiss Transfusion SRC

Completed

Seroprevalence Hepatitis E Infection in Healthy Blood Donors

Hepatitis E

Switzerland
Kantonsspital Olten

Completed

Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection

Pulmonary Artery Hypertension | Chronic Hepatitis c

Switzerland
University Hospital, Geneva
Gastaldi Giacomo; Clément Sophie

Completed

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Insulin Resistance

Switzerland
University of Zurich

Completed

Viral Reactivation and Skin Cancer

Skin Cancer | Infection Reactivation

Switzerland
University of Bern
Roche Pharma AG; University of Lausanne; University of Basel; Cantonal Hospital... and other collaborators

Completed

High Dose Ribavirin in the Treatment of Chronic Hepatitis C

Chronic Hepatitis C

Switzerland
University of Lausanne Hospitals

Completed

What is the Anti-HAV Seroprevalence of Travelers >60 Years or Having Lived in a Tropical Country for >5 Years (AHAV)

Hepatitis A

Switzerland
University of Zurich

Completed

Swiss HCVree Trial (HCVree)

Hepatitis C | HIV

Switzerland
University of Zurich

Completed

THISTLE - The HIV-HCV Silibinin Trial (THISTLE)

Hepatitis C | HIV

Switzerland
University of Oxford
GlaxoSmithKline; Cantonal Hospital of St. Gallen; St. James's Hospital, Ireland; ReiThera Srl

Completed

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

Hepatitis C Infection

Switzerland, Ireland
AbbVie

Completed

Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) (HEMATITE)

Chronic Hepatitis C Virus (HCV)

Switzerland
University Hospital, Basel, Switzerland
Kantonsspital St. Gallen, St. Gallen, Switzerland

Recruiting

Seroprevalence of Leptospirosis in Val Müstair, Switzerland

Leptospirosis | Tularemia | Hepatitis E Virus Infection

Switzerland
Novartis Vaccines

Completed

A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of a Monovalent Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18-40 Years of Age

Invasive Group B Streptococcus (GBS) Disease

Switzerland
Novartis Vaccines

Completed

A Phase I, Randomized, Single-blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of a Dose Range of Glycoconjugate Antigen Vaccine of Group B Streptococcus in Healthy Women 18- 40 Years of Age

Invasive Group B Streptococcus (GBS) Disease

Switzerland
Fondazione Epatocentro Ticino

Recruiting

Swiss Autoimmune Hepatitis Cohort Study

Hepatitis, Autoimmune

Switzerland
University Hospital, Basel, Switzerland

Completed

Cobalamin Deficiency - Diagnosis and Therapy

Vitamin B 12 Deficiency

Switzerland
University Hospital, Basel, Switzerland
University of Basel; Aarelab AG

Completed

Vitamin B12 Acceptance and Biomarker Response Study

Vitamin B 12 Deficiency

Switzerland
Novartis Pharmaceuticals

Terminated

Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

Hepatitis C | Liver Transplant

United States, Switzerland
Oncology Institute of Southern Switzerland

Recruiting

Liquid Biopsy in Mature B-cell Tumors

Mature B-Cell Neoplasm

Switzerland
Cytheris SA

Completed

Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1) (ECLIPSE 1)

Hepatitis C

France, Switzerland, Italy
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Lymphoma, B Cell

Switzerland
Cytheris SA

Unknown

Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone (Eclipse 2)

Hepatitis C

France, Switzerland, Italy
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

Lymphoma, B Cell

Switzerland
Novartis Vaccines

Completed

A Study to Assess the Persistence of Two GBS Antibodies in Women Previously Immunized With a GBS Vaccine

Group B Streptococcus (GBS) Disease

Switzerland
Novartis
Novartis Vaccines

Completed

A Study to Assess the Persistence of a GBS Antibody in Women Previously Immunized With a GBS Vaccine

Group B Streptococcus (GBS) Disease

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Terminated

VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

Lymphoma, Mucosa-Associated Lymphoid Tissue

Switzerland
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant

Hepatitis C Virus Infection

Spain, Switzerland, United Kingdom
International Extranodal Lymphoma Study Group (IELSG)

Completed

Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma

Splenic Marginal Zone Lymphoma

Switzerland
International Extranodal Lymphoma Study Group (IELSG)

Completed

Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

Marginal Zone B-cell Lymphoma

Italy, Switzerland, Austria
University Hospital, Geneva

Completed

Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis

Keratitis; Infectious Disease (Manifestation)

Switzerland
Janssen Pharmaceutica N.V., Belgium

Completed

Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C (INTEGRATE)

Hepatitis, Chronic

France, United Kingdom, Belgium, Germany, Netherlands, Switzerland
Blueprint Medicines Corporation

Completed

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Systemic Mast Cell Activation | KIT D816V Mutation

United States, France, United Kingdom, Italy, Germany, Belgium, Spain, Switzerland
University of Zurich

Completed

Determination of Blood Tumor Cells

Leukemia, Lymphocytic, Chronic, B-Cell | Abnormalities Cell Epithelial

Switzerland
Cristiana Sessa

Completed

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma (IOSI-LND-001)

B-cell Lymphoma Refractory

Switzerland
Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
University of Zurich

Unknown

Lymphoma in the Orbit

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Switzerland
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland

Clinical Trials on Hepatitis B Reactivation in Switzerland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations